The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
“One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells,” said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. “In the GAPVAC trial we will treat glioblastoma patients with vaccines that are ideal for each patient because they contain personalised antigens.”1
For all patients in the GAPVAC study, researchers will identify genes expressed in the tumour, peptides presented on the human leukocyte antigen (HLA) receptor (i.e. peptides which will be seen by T-cells), cancer specific mutations, and the ability of the immune system to mount a response to certain antigens. Based on this information, two vaccines, called actively personalised vaccines (APVACs), will be constructed and administered following conventional surgery.
The first vaccine will be prepared from a warehouse of 72 targets previously identified by the researchers as relevant for treatment in glioblastoma. These peptides have been manufactured and put on the shelf ready to be vaccinated in patients. Patients will be given a cocktail of the peptides they express and which their immune system can mount a response to.
Singh said: “A patient may express 20 of these 72 targets on their tumour, for example. If we find that the patient’s immune system can mount responses to 5 of the 20 targets, we mix the 5 peptides and give them to the patient. We mix the peptides off the shelf but the cocktail is changed for each patient because it is matched to their biomarkers.”
The second vaccine is synthesised de novo based on a mutated peptide expressed in the tumour of the patient. Singh said: “That peptide is not in our warehouse because it just occurs in this one single patient. The patient receives APVAC-1 and APVAC-2 in a highly personalised fashion in a way that I think has never been done for any patient.”
He added: “GAPVAC has two major goals. One is to show that personalised vaccines are feasible, since this is one of the most complicated trials ever done in cancer immunotherapy. The second is to show that we can mount far better biological responses in these patients compared to vaccination with non-personalised antigens.”
Singh’s previous research has shown that vaccination with non-personalised antigens leads to better disease control and longer overall survival in phase I and phase II clinical studies in patients with renal cell cancer.2
Singh said: “For the non-personalised vaccines we used off-the-shelf peptide targets that were shared by many patients with a particular cancer. Using this approach we have successfully vaccinated patients with renal cell cancer, colorectal cancer and glioblastoma.”
He added: “During this research we identified other targets that appeared in very few patients or even, in extreme cases, in a single patient. Often these rarer peptides are of better quality, meaning they are more specifically seen in cancer cells and occur at higher levels. This led us to start developing personalised cancer vaccines which contain the ideal set of targets for one particular patient. We hope they will be even more effective than the off-the-shelf vaccines.”
The Latest on: Personalised Vaccines
via Google News
The Latest on: Personalised Vaccines
- AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19on February 25, 2021 at 7:48 pm
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced the completion of a Phase 1 clinical ...
- BioIVT Unveils COVID-19 Panel to Accelerate Vaccine-Generated Immune Response Researchon February 25, 2021 at 1:46 pm
Panel contains serum or peripheral blood mononuclear cells (PBMCs) isolated from pre- and post-vaccination blood samples ...
- Report: One Medical gave ineligible people the COVID-19 vaccineon February 25, 2021 at 9:15 am
San Francisco-based health care provider One Medical has come under fire in California, Oregon and Washington for allegedly inoculating young, healthy people who were ineligible for the COVID-19 ...
- UPMC accepting appointments for COVID-19 vaccineon February 24, 2021 at 5:56 pm
One of the biggest healthcare providers in our region is being added to the list of vaccination clinics the public can go to. UPMC will now provide vaccinations to everyone in phase ...
- Big jump in COVID-19 vaccine supply is coming soon, drug executives sayon February 23, 2021 at 12:33 pm
COVID-19 vaccine makers told Congress on Tuesday to expect a big jump in the delivery of doses over the coming month after a rocky start to inoculations, and the companies insist they will be able ...
- Black Americans are bearing the brunt of the pandemic. Here's how to make the vaccine rollout more equitableon February 23, 2021 at 11:28 am
Bhaskar Chakravorti writes that the first step to fixing this inequity is acknowledging that Covid-19 is more than a public health crisis and an economic crisis; it is also an information crisis.
- Walmart providing free COVID-19 vaccines in Centre Countyon February 23, 2021 at 10:26 am
Walmart will begin administering the Pfizer COVID-19 vaccines in Centre County this week, according to a release. From Feb. 25 through Feb. 27., eligible patients ...
- Combatting Vaccine Hesitancy and Public Confusion: 5 Tips for More Compelling Communicationson February 22, 2021 at 11:33 am
Remind people that the vaccine will not only keep them healthy, it will also provide health benefits to their families and communities. Many individuals are concerned about possible side effects of ...
- Universal Orlando Resort Announces A NEW Vaccine Planning Toolon February 19, 2021 at 10:55 am
UNIVERSAL ORLANDO RESORT dropped a note to social media about a new website helping you find out more about the COVID VACCINE. This website will help you plan out when, where and how you can get your ...
- Anthem, CloudMedx bringing COVID-19 tracking tool to vaccine distributionon February 17, 2021 at 3:10 pm
Anthem and CloudMedx are adding vaccine distribution data to their online COVID-19 data platform. The two companies joined forces to launch C19 Explorer last summer, and that tool allows public health ...
via Bing News